Company intelligence / Profile preview

Aptahem

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Aptahem is a clinical-stage Swedish biotech company developing aptamer-based therapeutics for acute life-threatening conditions, primarily sepsis. Its lead candidate, APTA‑1, has advanced to Phase 1 clinical trials. The company collaborates with academic institutions and is expanding its pipeline to other inflammatory indications.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: AptamerRNA therapy
Industry: Biotech

Drug pipeline

3 assets

Apta-2

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Örebro UniversitySeattle Children’s Research InstituteUniversity Health NetworkHongene Biotech

Beyond the preview

Go deeper on Aptahem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aptahem.

Explore the full profile